An open-label, multicenter study to evaluate the efficacy and tolerability of a 4 week therapy with the fixed dose combination of valsartan 160 mg plus HCTZ 25 mg in hypertensive patients not adequately responding to a 4 week therapy with the free combination of an angiotensin receptor blocker (candersartan 32 mg) plus HCTZ 25 mg.

Trial Profile

An open-label, multicenter study to evaluate the efficacy and tolerability of a 4 week therapy with the fixed dose combination of valsartan 160 mg plus HCTZ 25 mg in hypertensive patients not adequately responding to a 4 week therapy with the free combination of an angiotensin receptor blocker (candersartan 32 mg) plus HCTZ 25 mg.

Completed
Phase of Trial: Phase III

Latest Information Update: 07 Nov 2011

At a glance

  • Drugs Candesartan cilexetil; Hydrochlorothiazide; Valsartan/hydrochlorothiazide
  • Indications Essential hypertension
  • Focus Therapeutic Use
  • Acronyms CICERO
  • Sponsors Novartis
  • Most Recent Events

    • 07 Nov 2011 Additional trial location (Switzerland) identified as reported by ClinicalTrials.gov.
    • 08 Jun 2011 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top